Indegene Limited IPO
₹430 - ₹452
33
70.3
| Open Date: | 06-May-2024 |
| Close Date: | 08-May-2024 |
| Allotment Date: | 09-May-2024 |
| Listing Date: | 13-May-2024 |
| Listing Price: | N/A |
| Face Value: | ₹2 Per Equity Share |
| Issue Price: | ₹430-452 Per Equity Share |
| Issue Size: | Total Issue Size 40,746,891 shares (aggregating up to ₹1,841.76 Cr) : Fresh Issue 16,814,159 shares (aggregating up to ₹760.00 Cr) : Offer for Sale 23,932,732 shares of ₹2 (aggregating up to ₹1,081.76 Cr) |
| Market Lot (Min Amount): | Retail - ₹14,916 : S-HNI - ₹208,824 : B-HNI - ₹1,014,288 |
As on | QIB | Nll | Rll | EMP | Total |
|---|---|---|---|---|---|
| Shares Offered/Reserved | 8,094,069 | 6,070,552 | 14,164,620 | 296,209 | 28,625,450 |
| Day 1 - 06-05-24 05:00 PM | 0.05x | 4.25x | 1.56x | 1.41x | 1.70x |
| Day 2 - 07-05-24 05:00 PM | 5.45x | 18.44x | 3.94x | 3.40x | 7.44x |
| Day 3 - 08-05-24 05:00 PM | 192.72x | 55.91x | 7.86x | 6.62x | 70.30x |
| Total No. of Application: | 2,793,616 (Approx.) | ||||
| Retail Subscription on the basis of Apps: | 6.51x | ||||
| Earning Per Share(EPS) | ₹11.96/- |
| P/E Ratio | 37.78 |
| RoNW | 18.23% |
| Net Asset Value (NAV) - Post Issue: | ₹N/A/- |
| Total Assets | Total Revenue | Profit After Tax | |
|---|---|---|---|
| 31 Dec,2023 | 2,518.15 | 1,969.75 | 241.90 |
| 31 Mar,2023 | 2,203.87 | 2,364.10 | 266.10 |
| 31 Mar,2022 | 1,353.47 | 1,690.50 | 162.82 |
| 31 Mar,2021 | 596.04 | 996.92 | 149.41 |
| Pre Issue Share Holding | 30.71% |
| Post Issue Share Holding | N/A% |
| 1. BCP Topco VII Pte. Ltd. |
The Company proposes to utilise the Net Proceeds towards funding the following objects:
- Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc.;
- Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.; and
- General corporate purposes and inorganic growth.
Founded in 1998, Indegene Limited provides digital services for the life sciences industry. They assist with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales/marketing support.
The company's services can be divided into following categories
- Enterprise Commercial Solutions
- Omnichannel Activation
- Enterprise Medical Solutions
- Enterprise Clinical Solutions and consultancy services
The subsidiary of the company, DT Associates Limited, provides consulting services under the "DT Consulting" brand. It helps life sciences companies manage their digital transformation efforts to ensure continued success in customer experience.
The company received the Platinum Level award at the 2023 Healthy Workplace Conference and Awards, a recognition given by Arogya World India Trust in partnership with the Public Health Foundation of India.
As of December 31, 2023, the company had 65 clients actively engaged with its services.
As of December 31, 2023, the company employed 5,181 people worldwide. Of these, 4,461 are based in India, 530 work in North America, 105 in Europe, 73 in China, and 12 in other regions.
No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.
If you are agree with app tems and condition to use the app.
Thank you.